Evaluation of the Feasibility of a Web-Based Survey to Assess Patient-Reported Symptom Improvement and Treatment Satisfaction Among Patients with Psoriatic Arthritis Receiving Secukinumab.
Journal
Clinical drug investigation
ISSN: 1179-1918
Titre abrégé: Clin Drug Investig
Pays: New Zealand
ID NLM: 9504817
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
pubmed:
25
9
2019
medline:
29
1
2020
entrez:
25
9
2019
Statut:
ppublish
Résumé
Patient perspectives regarding treatment experience and satisfaction may be useful for clinicians when making treatment strategies. This US-based study assessed the feasibility of evaluating real-world, patient-reported narratives regarding symptom improvement and treatment satisfaction among patients with psoriatic arthritis treated with secukinumab. A cross-sectional, web-based survey collected data on demographics, disease characteristics, symptoms before and after secukinumab use, and treatment satisfaction with secukinumab. Of 2755 patients screened, 200 patients with psoriatic arthritis were eligible and included in the analysis. Their mean age was 36.0 (standard deviation, 10.0) years; 55.5% were male and 75.0% were white. Most (87.5%) were biologic experienced; the primary reason for discontinuation of their previous treatment was lack of effectiveness (28.6%). Most patients (79.9%) reported overall psoriatic arthritis symptom improvement after secukinumab initiation compared with before secukinumab initiation; a similar trend was observed for all individual symptoms evaluated. Approximately half of patients reported improvement within 4 weeks after starting secukinumab treatment, and > 90% reported improvement within 6 months. Most patients (≥ 96%) expressed overall satisfaction with secukinumab regarding symptom improvement, speed of symptom improvement, frequency of administration, method of administration, ease of use, patient support services, and side effects, if any. Patient-reported perspectives may be feasibly collected to provide insights into treatment experience and satisfaction of secukinumab. Most patients with psoriatic arthritis in our real-world study experienced symptom improvement after initiating secukinumab; > 50% of patients reported symptom improvement within 4 weeks. Additionally, almost all patients reported satisfaction with secukinumab treatment.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Patient perspectives regarding treatment experience and satisfaction may be useful for clinicians when making treatment strategies. This US-based study assessed the feasibility of evaluating real-world, patient-reported narratives regarding symptom improvement and treatment satisfaction among patients with psoriatic arthritis treated with secukinumab.
METHODS
METHODS
A cross-sectional, web-based survey collected data on demographics, disease characteristics, symptoms before and after secukinumab use, and treatment satisfaction with secukinumab.
RESULTS
RESULTS
Of 2755 patients screened, 200 patients with psoriatic arthritis were eligible and included in the analysis. Their mean age was 36.0 (standard deviation, 10.0) years; 55.5% were male and 75.0% were white. Most (87.5%) were biologic experienced; the primary reason for discontinuation of their previous treatment was lack of effectiveness (28.6%). Most patients (79.9%) reported overall psoriatic arthritis symptom improvement after secukinumab initiation compared with before secukinumab initiation; a similar trend was observed for all individual symptoms evaluated. Approximately half of patients reported improvement within 4 weeks after starting secukinumab treatment, and > 90% reported improvement within 6 months. Most patients (≥ 96%) expressed overall satisfaction with secukinumab regarding symptom improvement, speed of symptom improvement, frequency of administration, method of administration, ease of use, patient support services, and side effects, if any.
CONCLUSIONS
CONCLUSIONS
Patient-reported perspectives may be feasibly collected to provide insights into treatment experience and satisfaction of secukinumab. Most patients with psoriatic arthritis in our real-world study experienced symptom improvement after initiating secukinumab; > 50% of patients reported symptom improvement within 4 weeks. Additionally, almost all patients reported satisfaction with secukinumab treatment.
Identifiants
pubmed: 31549346
doi: 10.1007/s40261-019-00856-8
pii: 10.1007/s40261-019-00856-8
pmc: PMC6842331
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
secukinumab
DLG4EML025
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1205-1212Références
Am J Clin Dermatol. 2016 Feb;17(1):87-97
pubmed: 26718712
Lancet. 2015 Sep 19;386(9999):1137-46
pubmed: 26135703
Arthritis Rheum. 2012 Aug;64(8):2504-17
pubmed: 22378566
Ann Rheum Dis. 2016 Apr;76(4):673-680
pubmed: 27613807
Arthritis Rheum. 2005 Oct;52(10):3279-89
pubmed: 16200601
Ann Rheum Dis. 2005 Aug;64(8):1150-7
pubmed: 15677701
Expert Opin Biol Ther. 2018 Sep;18(9):931-935
pubmed: 30044656
Value Health. 2007 Sep-Oct;10(5):326-35
pubmed: 17888097
JAMA Dermatol. 2013 Oct;149(10):1180-5
pubmed: 23945732
Clin Rheumatol. 2017 Sep;36(9):2045-2054
pubmed: 28238086
Inquiry. 1988 Spring;25(1):25-36
pubmed: 2966123
Rheumatology (Oxford). 2009 Jan;48(1):53-6
pubmed: 18977846
Rheumatology (Oxford). 2017 Apr 1;56(4):597-602
pubmed: 28013202
Rheum Dis Clin North Am. 2009 Nov;35(4):773-8, viii
pubmed: 19962621
Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii14-7
pubmed: 15708927
N Engl J Med. 2015 Oct;373(14):1329-39
pubmed: 26422723
J Am Acad Dermatol. 2013 Nov;69(5):729-735
pubmed: 23981683
Arthritis Rheumatol. 2016 May;68(5):1060-71
pubmed: 26749174
Ann Rheum Dis. 2017 Jan;76(1):203-207
pubmed: 27169431
Clin Exp Rheumatol. 2015 Jan-Feb;33(1):11-9
pubmed: 25535650
Med Care. 1997 Nov;35(11 Suppl):NS58-68
pubmed: 9366880
J Am Acad Dermatol. 2005 Oct;53(4):573
pubmed: 16198775
J Rheumatol. 2015 Oct;42(10):1781-5
pubmed: 26233511
Rheum Dis Clin North Am. 2015 Nov;41(4):569-79
pubmed: 26476219
Arthritis Res Ther. 2019 May 2;21(1):111
pubmed: 31046809
Ann Rheum Dis. 2018 Jun;77(6):890-897
pubmed: 29550766
Curr Opin Rheumatol. 2017 Mar;29(2):144-149
pubmed: 28072590
Rheumatology (Oxford). 2015 Jan;54(1):20-8
pubmed: 25125588
Drugs Real World Outcomes. 2019 Jun;6(2):83-91
pubmed: 31054047